About Event
What You Missed: The 2nd Annual Optimizing AAV Safety Summit 2023
In 2023 we discussed the optimization of the prediction of different safety signals, learnt more about monitoring the safety of AAV therpaies across preclinical and clinical development and actively mitigated against high-risk safety related adverse events to safeguard patient outcomes.
Check out our 2023 event guide to see what 2024 potentially has in store.
What You Missed:
The Insights:
Evaluated the current opportunities and limitations of using animal models to optimize AAV safety in preclinical trials with an interactive panel discussion with Prevail Therapeutics, Kate Therapeutics, Lactera and more to better understand how AAV vectors behave in humans
Explored the key immunogenicity concerns associated with AAV vector safety and learn strategies to mitigate against neutralizing antibodies and understand the mechanism of complement activation with Selecta Biosciences and Apsa Therapeutics
Navigated how to effectively monitor AAV safety signals across different target indications with Neurogene, Ultragenyx Pharmaceuticals, Lacerta and more to optimize the safety of individual AAV therapies
Debated and critically assessed the oncogenic risk associated with AAV therapies to characterize the risk of AAV vector genome integration and leverage the latest preclinical updates to formulate long-term plans to monitor oncogenic risk with BioMarin and Indianna University
Dove into the reliability of current testing methods and biomarkers to accurately provide information on the safety profile of different AAVs with Neurogene and Voyager to improve translational success and patient outcomes
What Your Peers Had To Say:
"This was an excellent overview of many of the vexing issues that surround AAV and safety, with perspectives shared by academic experts and company representatives"
A past Optimizing AAV Safety Summit attendee, National Institute of Health Science
